362 related articles for article (PubMed ID: 33131178)
21. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
[TBL] [Abstract][Full Text] [Related]
22. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
[TBL] [Abstract][Full Text] [Related]
23. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
[TBL] [Abstract][Full Text] [Related]
24. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz J; Spengler U; Müllhaupt B; Schulze Zur Wiesch J; Piecha F; Mauss S; Seegers B; Hinrichsen H; Antoni C; Wietzke-Braun P; Peiffer KH; Berger A; Matschenz K; Buggisch P; Backhus J; Zizer E; Boettler T; Neumann-Haefelin C; Semela D; Stauber R; Berg T; Berg C; Zeuzem S; Vermehren J; Sarrazin C;
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):195-198.e2. PubMed ID: 31706062
[TBL] [Abstract][Full Text] [Related]
28. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes.
Fourati S; Rodriguez C; Soulier A; Donati F; Hamadat S; Poiteau L; Demontant V; Brillet R; Ahnou N; Gricourt G; Chevaliez S; Ahmed-Belkacem A; Pawlotsky JM
Aliment Pharmacol Ther; 2020 Nov; 52(10):1583-1591. PubMed ID: 32886807
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
Rossetti B; Paglicci L; Di Maio VC; Cassol C; Barbaliscia S; Paolucci S; Bruzzone B; Coppola N; Montagnani F; Micheli V; Monno L; Zanelli G; Santantonio T; Cuomo N; Caudai C; Zazzi M; Ceccherini-Silberstein F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet C
Infez Med; 2021 Jun; 29(2):242-251. PubMed ID: 34061790
[TBL] [Abstract][Full Text] [Related]
30. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
[TBL] [Abstract][Full Text] [Related]
32. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
Zeuzem S; Mizokami M; Pianko S; Mangia A; Han KH; Martin R; Svarovskaia E; Dvory-Sobol H; Doehle B; Hedskog C; Yun C; Brainard DM; Knox S; McHutchison JG; Miller MD; Mo H; Chuang WL; Jacobson I; Dore GJ; Sulkowski M
J Hepatol; 2017 May; 66(5):910-918. PubMed ID: 28108232
[TBL] [Abstract][Full Text] [Related]
33. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
[TBL] [Abstract][Full Text] [Related]
34. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
35. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.
Hong CM; Lin YY; Liu CJ; Lai YY; Yeh SH; Yang HC; Kao JH; Hsu SJ; Huang YH; Yang SS; Kuo HT; Cheng PN; Yu ML; Chen PJ
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835100
[TBL] [Abstract][Full Text] [Related]
36. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
[TBL] [Abstract][Full Text] [Related]
37. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
[TBL] [Abstract][Full Text] [Related]
38. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
[TBL] [Abstract][Full Text] [Related]
40. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
Sorbo MC; Carioti L; Bellocchi MC; Antonucci F; Sforza D; Lenci I; Ciancio Manuelli M; Armenia D; De Leonardis F; Milana M; Manzia TM; Angelico M; Tisone G; Cento V; Perno CF; Ceccherini-Silberstein F
Liver Int; 2019 Oct; 39(10):1986-1998. PubMed ID: 31172639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
